Administration of procainamide, flecainide, or ajmaline may be useful to provoke type 1 ST elevation in patients suspected to have Brugada syndrome as a cause of symptoms but who do not have a type 1 electrocardiographic pattern at baseline. Medication challenge should be ter- minated with the development of VA, marked QRS widening, or type 1 Brugada electrocardio- The use of high electrocardiographic electrode positioning in the second and third interspaces for electrocardio- graphic recording improves detection of a type Asymptomatic patients with a family history of Brugada syndrome may be offered sodium channel blocker challenge for diagnostic evaluation, although a positive test does not require chronic therapy due to a low risk in this setting.S7.9.1.3-12 In asymptomatic patients with type 1 Brugada electrocardiographic find- ings, medication challenge does not offer addi- tional diagnostic value. 6. Polymorphic VT/VF induced by programmed stim- ulation has been associated with an increased risk of VA in some patients with spontaneous type The specificity of pro- grammed stimulation for assessing risk decreases with the inclusion of triple extrastimuli.S7.9.1.3-6, The value of programmed stimulation in asymptomatic patients with spontaneous type 1 Brugada ECGs has been the subject of mul- A report found that the prognostic value has decreased over time, possibly as patients with less severe phenotypes have been recognized and Some experts use the results of programmed ventricular stimulation for inform- ing shared decision-making in consideration of the ICD. In symptomatic patients with Brugada syndrome, programmed ventricular stimula- tion for risk stratification does not add anything to the evaluation of the patients as an ICD is 7. The yield of genetic testing in phenotype positive patients is approximately 20% to 30% in Brugada SCN5A variants account for most of this subset of genotype positive Brugada syndrome. 